PARASYMPATHOLYTICS

 

INTRODUCTION:  Drugs that block the action of Acetylcholine are known by a number of names, including anticholinergics, cholinergic blockers, muscarinic antagonists, and parasympatholytics.  Although the term anticholinergic is most commonly used, the most accurate term for this class of drugs is muscarinic antagonists, because at therapeutic doses, these drugs are selective for Ach muscarinic receptors and thus have little effect on Ach nicotinic receptors.

PHARMACODYNAMICS:  Anticholinergics act by competing with Ach for binding muscarinic receptors. When anticholinergics occupy these receptors, no response is generated at the neuroeffector organs. Suppressing the effects of Ach causes symptoms of sympathetic nervous system activation to predominate. Most therapeutic uses of the anticholinergics are predictable extensions of their parasympathetic-blocking actions: dilation of the pupils, increase in heart rate, drying of secretions, and relaxation of the bronchi.

THERAPEUTIC USES:  1. GI disorders:  These agents decrease the secretion of gastric acid in peptic ulcer disease. They also slow intestinal motility and may be useful for reducing the cramping and diarrhea associated with irritable bowel syndrome. 

2. Ophthalmic procedures:  Anticholinergics may be used to cause mydriasis or cycloplegia during eye procedures.

3. Cardiac rhythm abnormalities:  Anticholinergics can be used to accelerate the heart rate in patients experiencing bradycardia.

4. Preanesthesia:  Combined with other agents, anticholinergics can decrease excessive respiratory secretions and reverse the bradycardia caused by general anesthetics.

5. Asthma:  A few agents, such as ipratropium, are useful in treating asthma, because of their ability to dilate the bronchi.

6. Overactive bladder:  Anticholinergics treat urinary retention and incontinence.

7. Degenerative nervous system application:  Anticholinergics are used to treat patients who have Parkinson’s disease and whose main symptom is tremor. The prototype drug, atropine, is used for several additional medical conditions due to its effective muscarinic receptor blockade. These applications include reversal of adverse muscarinic effects and treatment of cholinergic agent poisoning, including that caused by overdose of bethanechol, cholinesterase inhibitors, or accidental ingestion of certain types of mushrooms or organophosphate pesticides.

 

RELATED;

1.  ACETYLCHOLINE

2.  CHOLINOMIMETICS

3.  GENERATION OF A NERVE IMPULSE

4.  DIVISIONS OF THE CENTRAL NERVOUS SYSTEM

5.  ATROPINE

REFERENCES

IMIPRAMINE

 

Therapeutic Class: Antidepressant; treatment of nocturnal enuresis in children

Pharmacologic Class: Tricyclic antidepressant

ACTIONS AND USES: Imipramine blocks the re-uptake of serotonin and norepinephrine into nerve terminals. It is used mainly for major depression, although it is occasionally used for the treatment of nocturnal enuresis (bed wetting) in children. It may also be prescribed for a number of unlabeled uses, including intractable pain, anxiety disorders, and withdrawal syndromes from alcohol and cocaine. Therapeutic effectiveness may not occur for 2 or more weeks.

ADMINISTRATION ALERTS: Paradoxical diaphoresis can be a side effect of TCAs; therefore, diaphoresis may not be a reliable indicator of other disease states such as hypoglycemia.

Imipramine causes anticholinergic effects and may potentiate effects of anticholinergic drugs administered during surgery. Do not discontinue abruptly because rebound dysphoria, irritability, or sleeplessness may occur. Pregnancy category C.

ADVERSE EFFECTS: Side effects include sedation, drowsiness, blurred vision, dry mouth, and cardiovascular symptoms such as dysrhythmias, heart block, and extreme hypertension. Agents that mimic the action of norepinephrine or serotonin should be avoided because imipramine inhibits their metabolism and may produce toxicity. Some patients may experience photosensitivity and hypersensitivity to tricyclic drugs.

Warning: Antidepressants increase the risk of suicidal thinking and behavior, especially in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. This drug is not approved for use in pediatric patients. 

Contraindications: This drug should not be used in cases of acute recovery after MI, defects in bundle-branch conduction, narrow-angle glaucoma, and severe renal or hepatic impairment. Patients should not use this drug within 14 days of discontinuing MAOIs. 

INTERACTIONS: Drug–Drug: Concurrent use of other CNS depressants, including alcohol, may cause sedation. Cimetidine may inhibit the metabolism of imipramine, leading to increased serum levels and possible toxicity. Imipramine may reverse the antihypertensive effects of clonidine and potentiate CNS depression. Use of oral contraceptives may increase or decrease imipramine levels. Disulfiram may lead to delirium and tachycardia. Antithyroid agents may produce agranulocytosis. Phenothiazines cause increased anticholinergic and sedative effects. Sympathomimetics may result in cardiac toxicity. Methylphenidate or cimetidine may increase the effects of imipramine and cause toxicity. Phenytoin is less effective when taken with imipramine. MAOIs may result in neuroleptic malignant syndrome.

RELATED;

1.  DEPRESSION

2.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

DRUG METABOLISM

Introduction:  Metabolism, also called biotransformation, is the process of chemically converting a drug to a form that is usually more easily removed from the body. Metabolism involves complex biochemical pathways and reactions that alter drugs, nutrients, vitamins, and minerals. The liver is the primary site of drug metabolism, although the kidneys and cells of the intestinal tract also have high metabolic rates. Medications undergo many types of biochemical reactions as they pass through the liver, including hydrolysis, oxidation, and reduction.

Microsomal enzyme systems:  During metabolism, the addition of side chains, known as conjugates, makes drugs more water soluble and more easily excreted by the kidneys. Most metabolism in the liver is accomplished by the hepatic microsomal enzyme system. This enzyme complex is sometimes called the P-450 system, named after cytochrome P-450 (CYP-450), which is a key component of the system. The cytochrome P450 enzyme system

Enzyme induction and the role of prodrugs:  As they relate to pharmacotherapy, the primary actions of the hepatic microsomal enzymes are to inactivate drugs and accelerate their excretion. In some cases, however, metabolism can produce a chemical alteration that makes the resulting molecule more active than the original. For example, the narcotic analgesic codeine undergoes biotransformation to morphine, which has significantly greater ability to relieve pain. In fact, some agents, known as prodrugs, have no pharmacologic activity unless they are first metabolized to their active form by the body. Examples of prodrugs include benazepril and, proinsulin and losartan. Changes in the function of the hepatic microsomal enzymes can significantly affect drug metabolism. A few drugs have the ability to increase metabolic activity in the liver, a process called enzyme induction. For example, phenobarbital causes the liver to synthesize more microsomal enzymes. By doing so, phenobarbital increases the rate of its own metabolism as well as that of other drugs metabolized in the liver. In these patients, higher doses of medication may be required to achieve the optimum therapeutic effect. 

Considerations for liver functioning states:  Certain patients have decreased hepatic metabolic activity, which may alter drug action. Hepatic enzyme activity is generally reduced in infants and elderly patients; therefore, pediatric and geriatric patients are more sensitive to drug therapy than middle-age patients. Patients with severe liver damage, such as that caused by cirrhosis, will require reductions in drug dosage because of the decreased metabolic activity. Certain genetic disorders have been recognized in which patients lack specific metabolic enzymes; drug dosages in these patients must be adjusted accordingly. Metabolism has a number of additional therapeutic consequences.  

The roles of fast-pass effect:  For example, drugs absorbed after oral administration cross directly into the hepatic portal circulation, which carries blood to the liver before it is distributed to other body tissues. Thus, as blood passes through the liver circulation, some drugs can be completely metabolized to an inactive form before they ever reach the general circulation. This first-pass effect is an important mechanism, since a large number of oral drugs are rendered inactive by hepatic metabolic reactions. Alternative routes of delivery that bypass the first-pass effect (e.g., sublingual, rectal, or parenteral routes) may need consideration for these drugs. 

RELATED;

1.  ABSORPTION  

2.  PHARMACOKINETICS

REFERENCES

DRUG ABSORPTION

 

Introduction: Absorption is a process involving the movement of a substance from its site of administration, across body membranes, to circulating fluids. Drugs may be absorbed across the skin and associated mucous membranes, or they may move across membranes that line the gastrointestinal (GI) or respiratory tract. Most drugs, with the exception of a few topical medications, intestinal anti-infectives, and some radiologic contrast agents, must be absorbed to produce an effect. Absorption is the primary pharmacokinetic factor determining the length of time it takes a drug to produce its effect. Pharmacokinetics

In order for a drug to be absorbed it must dissolve. The rate of dissolution determines how quickly the drug disintegrates and disperses into simpler forms; therefore, drug formulation is an important factor of bioavailability. Bioavailability

In general, the more rapid the dissolution, the faster the drug absorption and the faster the onset of drug action. For example, famotidine administered as an orally disintegrating tablet dissolves within seconds and after being swallowed is delivered to the stomach where it blocks acid secretion from the stomach, thereby treating conditions of excessive acid secretion. Pepticulcer disease: Histamine H2 receptor blockers

At the other extreme some drugs have shown good clinical response as slowly dissolving drugs such as liothyronine sodium (T3) and thyroxine (T4) administered for resolution of hypothyroid symptoms. In some instances it is advantageous for a drug to disperse rapidly. In other cases, it is better for the drug to be released slowly where the effects are more prolonged for positive therapeutic benefit. Absorption is conditional on many factors. Drugs in elixir or syrup formulations are absorbed faster than tablets or capsules. Drugs administered in high doses are generally absorbed more quickly and have a more rapid onset of action than those given in low concentrations. The speed of digestive motility, surface area, pH, lipid solubility, exposure to enzymes in the digestive tract, and blood flow to the site of drug administration also affect absorption. Because drugs administered IV directly enter the bloodstream, absorption to the tissues after the infusion is very rapid. IM medications take longer to absorb. Drug distribution

Other factors that influence the absorption of medications include the following: Drug formulation and dose, Size of the drug molecule, Surface area of the absorptive site, Digestive motility or blood flow, Lipid solubility, Degree of ionization, Acidity or alkalinity (pH), Interactions with food and other medications. The degree of ionization of a drug also affects its absorption. A drug’s ability to become ionized depends on the surrounding pH. Aspirin provides an excellent example of the effects of ionization on absorption. In the acid environment of the stomach, aspirin is in its non-ionized form and thus readily absorbed and distributed by the bloodstream. As aspirin enters the alkaline environment of the small intestine, however, it becomes ionized. In its ionized form, aspirin is not as likely to be absorbed and distributed to target cells.

Unlike acidic drugs, medications that are weakly basic are in their nonionized form in an alkaline environment; therefore, basic drugs are absorbed and distributed better in alkaline environments such as in the small intestine. The pH of the local environment directly influences drug absorption through its ability to ionize the drug.

Drug–drug or food–drug interactions may influence absorption. Many examples of these interactions have been discovered. For example, administering tetracyclines with food or drugs containing calcium, iron, or magnesium can significantly delay absorption of the antibiotic.  High-fat meals can slow stomach motility significantly and delay the absorption of oral medications taken with the meal. Dietary supplements may also affect absorption.

RELATED;

1.  DRUG DISTRIBUTION  

2.  PHARMACOKINETICS

3.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

ANTIBACTERIAL PROPERTIES OF GOLDENSEAL

 

INTRODUCTION:  Goldenseal (Hydrastis canadensis) was once a common plant found in woods in the eastern and midwestern United States. Native Americans used the root for a variety of medicinal applications, including skin diseases, ulcers, and gonorrhea. Recent uses include the treatment of colds and other respiratory tract infections, infectious diarrhea, eye infections, vaginitis, wounds, canker sores, and cancer.

Goldenseal was once reported to mask the appearance of drugs in the urine of patients wanting to hide drug abuse but this claim has since been proved false. The roots and leaves of goldenseal are dried and are available as capsules, tablets, salves, and tinctures. Two of the active ingredients in goldenseal are berberine and hydrastine, which are reported to have antibacterial properties.

When used topically or locally, goldenseal is claimed to be of value in treating bacterial and fungal skin infections and oral conditions such as gingivitis and thrush. As an eyewash, it can soothe inflamed eyes. Considered safe for most people, it is contraindicated in pregnancy and hypertension. Hypertension: Pregnancy and drug use

RELATED;

1.  GINSENG FOR CARDIOVASCULAR DISEASE  

2.  GARLIC FOR CARDIOVASCUAR DISEASE

REFERENCES

PROCHLORPERAZINE

Therapeutic Class: Antiemetic

Pharmacologic Class: Phenothiazine antipsychotic

ACTIONS AND USES: Prochlorperazine is a phenothiazine, a class of drugs usually prescribed for psychoses. The phenothiazines are the largest group of drugs prescribed for severe nausea and vomiting, and prochlorperazine is the most frequently prescribed antiemetic in its class. Prochlorperazine acts by blocking dopamine receptors in the brain, which inhibits signals to the vomiting center in the medulla. Dopamine

As an antiemetic, it is frequently given by the rectal route, where absorption is rapid. It is also available in tablet, extended-release capsule, and IM formulations.

ADMINISTRATION ALERTS: Administer 2 hours before or after antacids and antidiarrheals. Pregnancy category C.

ADVERSE EFFECTS: Prochlorperazine produces dose-related anticholinergic side effects such as dry mouth, sedation, constipation, orthostatic hypotension, and tachycardia. When used for prolonged periods at higher doses, extrapyramidal symptoms resembling those of Parkinson's disease are a serious concern, especially in older patients.

Contraindications: This drug should not be used in patients with hypersensitivity to phenothiazines, in comatose patients, or in the presence of profound CNS depression. It is also contraindicated in children younger than age 2. Patients with narrow-angle glaucoma, bone marrow suppression, or severe hepatic or cardiac impairment should not take this drug.

INTERACTIONS: Drug-Drug: Prochlorperazine interacts with alcohol and other CNS depressants to cause additive sedation. Antacids and antidiarrheals inhibit the absorption of prochlorperazine. When taken with phenobarbital, metabolism of prochlorperazine is increased. Use with tricyclic antidepressants may produce increased anticholinergic and hypotensive effects.

RELATED;

1. NAUSEA AND VOMITING  

2. ENTERIC NERVOUS SYSTEM

3.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

ECHINACEA FOR BOOSTING THE IMMUNE SYSTEM

 

Echinacea purpurea, or purple coneflower, is a popular botanical native to the midwestern United States and central Canada. The flowers, leaves, and stems of this plant are harvested and dried. Preparations include dried powder, tincture, fluid extracts, and teas. No single ingredient seems to be responsible for the herb’s activity; a large number of potentially active chemicals have been identified from the extracts. Echinacea was used by Native Americans to treat various wounds and injuries. Wound healing

Echinacea is believed to boost the immune system by increasing phagocytosis and inhibiting the bacterial enzyme hyaluronidase. Some substances in echinacea appear to have antiviral activity; thus, the herb is sometimes taken to treat the common cold and influenza, an indication for which it has received official approval in Germany. Clinical evidence for the effects of echinacea on upper respiratory tract infections is mixed, with some studies showing no effect and others showing a beneficial effect. In general, echinacea is used as a supportive treatment for any disease involving inflammation and to enhance the immune system. Inflammation: Immunity

Side effects are rare; however, it may interfere with drugs that have immunosuppressant effects.

RELATED;

1.  PASSIVE IMMUNITY  

2.  ACTIVE IMMUNISATION  

3.  SEA VEGETABLES

REFERENCES

GRAPE SEED EXTRACT FOR HYPERTENSION

 

Grapes and grape seeds have been to maintain and improve health used for thousands of years. Their primary use has been for cardiovascular conditions such as hypertension (HTN), high blood cholesterol, and atherosclerosis, and to generally improve circulation. Hypertension: Atherosclerosis

Some claim that grape seed extract improves wound healing, prevents cancer, slows the progression of neurodegenerative diseases, and lowers the risk for the long-term consequences of diabetes. Woundhealing: Diabetes

The grape seeds, usually obtained from winemaking, are crushed and placed into tablet, capsule, or liquid forms. Typical doses are 50 to 300 mg/ day. Grape seed extract has antioxidant properties that have the potential to improve wound healing and repair cellular injury. Grape seed extract is well tolerated in most people, with the most common side effects being dry, itchy scalp; dizziness; headache; hives; indigestion; and nausea. It has few adverse effects but caution should be used if taking anticoagulant drugs because increased bleeding may result.

RELATED;

1.  ARTERIOSCLEROSIS  

2.  GARLIC  

3.  BLOOD PRESSURE CONTROL

4.  TRADITIONAL AND COMPLIMENTARY MEDICATIONS

REFERENCES

HISTAMINE H2 RECEPTOR BLOCKERS

 

INTRODUCTION: Histamine has two types of receptors: H1 and H2. Activation of H1 receptors produces the classic symptoms of inflammation and allergy, whereas the H2 receptors are responsible for increasing acid secretion in the stomach. The H2-receptor antagonists are effective at suppressing the volume and acidity of parietal cell secretions. Duodenal ulcers usually heal in 6 to 8 weeks, and gastric ulcers may require up to 12 weeks of therapy. All of the H2-receptor antagonists are available OTC for the short-term (2 weeks) treatment of GERD.

Prototype Drug: Ranitidine

Therapeutic Class: Antiulcer drug

Pharmacologic Class: H2-receptor antagonist

ACTIONS AND USES: Ranitidine acts by blocking H2 receptors in the stomach to decrease acid production. It has a higher potency than cimetidine, which allows it to be administered once daily, usually at bedtime. Adequate healing of the ulcer takes approximately 4 to 8 weeks, although those at high risk for PUD may continue on drug maintenance for prolonged periods to prevent recurrence. Gastric ulcers require longer therapy for healing to occur. Intravenous (IV) and intramuscular (IM) forms are available for the treatment of acute, stress-induced bleeding ulcers. Ranitidine is available in a dissolving tablet form for treating GERD in children and infants older than 1 month of age. 

ADMINISTRATION ALERT: Administer after meals and monitor liver and renal function.

Pregnancy category B (Read about drug use in relation to pregnancy)

ADVERSE EFFECTS: Adverse effects are uncommon and mild. Ranitidine does not cross the blood–brain barrier to any appreciable extent, so it does not cause the confusion and

CNS depression observed with cimetidine. Although rare, severe reductions in the number of red and white blood cells and platelets are possible; thus, periodic blood counts may be performed. High doses may result in impotence or loss of libido in men.

Contraindications: Contraindications include hypersensitivity to H2-receptor antagonists, acute porphyria, and OTC administration in children less than 12years of age.

INTERACTIONS: Drug–Drug: Ranitidine has fewer drug–drug interactions than cimetidine. Ranitidine may reduce the absorption of cefpodoxime, ketoconazole, and itraconazole. Antacids should not be given within 1 hour of H2-receptor antagonists because the effectiveness may be decreased due to reduced absorption. Smoking decreases the effectiveness of ranitidine.

Lab Tests: Ranitidine may increase the values of serum creatinine, AST, ALT, LDH, alkaline phosphatase, and bilirubin. It may produce false positives for urine protein.

Herbal/Food: Absorption of vitamin B12 depends on an acidic environment; thus, deficiency may occur. Iron is also better absorbed in an acidic environment.

RELATED;

1. PROTON PUMP INHIBITORS  

2. ANTIBIOTICS  

3. PEPTIC ULCER DISEASE

4.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

GARLIC FOR CARDIOVASCULAR HEALTH

 

INTRODUCTION: Garlic also scientifically known as Allium sativum, is one of the best-studied herbs. Several substances, known as alliaceous oils, have been isolated from garlic and shown to have pharmacologic activity.

Dosage forms include eating prepared garlic oil or the fresh bulbs from the plant. Modern claims for garlic uses have focused on the cardiovascular system: treatment of high blood lipid levels, atherosclerosis, and hypertension. Other modern claims are that garlic reduces blood glucose levels and has antibacterial and antiviral properties. Like many other supplements, garlic likely has some health benefits, but controlled, scientific studies are often lacking and the results are mixed. Garlic has been shown to decrease the aggregation or “stickiness” of platelets, thus producing an anticoagulant effect. There is some research to show that the herb has a small effect on lowering blood cholesterol. Evidence on the effects of the herb on blood pressure is mixed. An analysis of the research of the effect of garlic on the common cold concluded that there is insufficient clinical evidence to show any benefit. Garlic is safe for consumption in moderate amounts. Patients taking anticoagulant medications should limit their intake of garlic to avoid bleeding complications. Patients with diabetes should monitor their blood glucose levels closely if taking high doses of garlic.

RELATED;

1.  CARDIOVASCULAR CONDITIONS

REFERENCES

ISONIAZID (INH)

 

Therapeutic Class: Antituberculosis drug

Pharmacologic Class: Mycolic acid inhibitor

Actions and uses: Isoniazid is a first-line drug for the treatment of M. tuberculosis because decades of experience have shown it to have a superior safety profile and to be the most effective, single drug for the infection. The drug acts by inhibiting the synthesis of mycolic acids, which are essential components of mycobacterial cell walls. It is bacteriocidal for actively growing organisms but bacteriostatic for dormant mycobacteria. It is selective for M. tuberculosis. Isoniazid may be used alone for chemoprophylaxis, or in combination with other antituberculosis drugs for treating active disease. Approximately 10% of patients will develop resistance to isoniazid during long-term therapy.

Administration alerts: Give on an empty stomach, 1 hour after or 2 hours before meals. For IM administration, administer deep IM, and rotate sites. The drug is pregnancy category C.

Adverse effects: The most common adverse effects of isoniazid are numbness of the hands and feet, rash, and fever. Neurotoxicity is a concern during therapy, and patients may exhibit paresthesia of the feet and hands, convulsions, optic neuritis, dizziness, coma, memory loss, and various psychoses.

Warning: Although rare, hepatotoxicity is a serious and sometimes fatal adverse effect; thus, the patient should be monitored carefully for jaundice, fatigue, elevated hepatic enzymes, or loss of appetite. Liver enzyme tests are usually performed monthly during therapy to identify early hepatotoxicity. Hepatotoxicity usually appears in the first 1 to 3 months of therapy but may occur at any time during treatment. Older adults and those with daily alcohol consumption are at greater risk of developing hepatotoxicity.

Contraindications: Isoniazid is contraindicated in patients with hypersensitivity to the drug and in patients with severe hepatic impairment.

Interactions: Drug–Drug: Aluminum-containing antacids should not be administered concurrently because they can decrease the absorption of isoniazid. When disulfiram is taken with INH, lack of coordination or psychotic reactions may result. Drinking alcohol with INH increases the risk of hepatotoxicity. Isoniazid may increase serum levels of phenytoin and carbamazepine.

Treatment of Overdose: Isoniazid overdose may be fatal. Treatment is mostly symptomatic. Pyridoxine (vitamin B6) may be infused in a dose equal to that of the isoniazid overdose to prevent seizures and to correct metabolic acidosis. The dose may be repeated several times until the patient regains consciousness

RELATED;

1. DRUG USE IN RELATION TO PREGNANCY  

2. TUBERCULOSIS

3.  ETHAMBUTOR

4.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

SEA VEGETABLES

Sea vegetables, or seaweeds, are a form of marine algae that grow in the upper levels of the ocean, where sunlight can penetrate. Examples of these edible seaweeds include spirulina, kelp, chlorella, arame, and nori, many of which are used in Asian cooking. Sea vegetables are found in coastal locations throughout the world. Kelp, or Laminaria, is found in the cold waters of the North Atlantic and Pacific Oceans. Sea vegetables contain a multitude of vitamins as well as protein. Their most notable nutritional aspect, however, is their mineral content. Plants from the sea contain more minerals than most other food sources, including calcium, magnesium, phosphorous, iron, potassium, and all essential trace elements. Because they are so rich in minerals, seaweeds act as alkalizers for the blood, helping to rid the body of acid conditions (acidosis). Spirulina, kelp, and chlorella are available in capsule or tablet form, or as part of a “greens” mix containing other nutritional ingredients.

RELATED;

1.  GINGER  

2.  GARLIC  

3.  FOOD-DRUG INTERACTIONS

4.  TRADITIONAL AND COMPLIMENTARY MEDICATIONS

REFERENCES

CATEGORIES OF DRUGS IN RELATION TO PREGNANCY

 

INTRODUCTION:  Drug use during pregnancy is one of the most important threats to worry about in order to ensure the safety of the mother and the baby.  In the first place although the mother may have less or no effect, our fear rotates around the growing fetus that may take in the drug via the placenta and develop fetal malformations.

1.  RISK CATEGORY A

INTERPRETATION: Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities to the fetus in any trimester of pregnancy.

EXAMPLE OF DRUGS: Prenatal multivitamins, insulin, thyroxine, folic acid.

2.  RISK CATEGORY B

INTERPRETATION: Animal studies have revealed no evidence of harm to the fetus; however, there are no adequate and well-controlled studies in pregnant women.

OR

Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate risk to the fetus in any trimester.

EXAMPLE OF DRUGS: Penicillins, cephalosporins, azithromycin, acetaminophen, ibuprofen in the first and second trimesters.

3.  RISK CATEGORY C

INTERPRETATION: Animal studies have shown an adverse effect and there are no adequate and well controlled studies in pregnant women.

OR

No animal studies have been conducted and there are no adequate and well controlled studies in pregnant women.

EXAMPLE OF DRUGS: Most prescription medicines; antimicrobials such as clarithromycin, fluoroquinolones, and Bactrim; selective serotonin reuptake inhibitors (SSRIs); corticosteroids; and most antihypertensives.

4.  RISK CATEGORY D

INTERPRETATION: Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

EXAMPLE OF DRUGS: Alcohol, ACE inhibitors, angiotensin receptor blockers (ARBs) in the second and third trimesters, gentamicin, carbamazepine, cyclophosphamide, lithium carbonate, methimazole, mitomycin, nicotine, nonsteroidal antiinflammatory drugs (NSAIDs) in the third trimester, phenytoin, propylthiouracil, streptomycin, tetracyclines, valproic acid.

5.  RISK CATEGORY X

INTERPRETATION: Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant. There is no indication for use in pregnancy.

EXAMPLE OF DRUGS: Clomiphene, fluorouracil, isotretinoin, leuprolide, menotropins, methotrexate, misoprostol, nafarelin, oral contraceptives, raloxifene, ribavirin, statins, temazepam, testosterone and thalidomide, and warfarin.

RELATED;

1.  HEMORRHAGIC DISEASE OF THE NEW BORN  

2.  ENDOMETRIOSIS

3.  OBSTETRICS AND GYNECOLOGY

REFERENCES

SULFONAMIDES

 

INTRODUCTION: Sulfonamides with varying physical, chemical, pharmacologic, and antibacterial properties are produced by attaching substituents to the amido group (–SO₂–NH–R) or the amino group (–NH₂ ) of the sulfanilamide nucleus. Sulfonamides tend to be much more soluble at alkaline than at acid pH. Most can be prepared as sodium salts, which are used for intravenous administration.

MECHANISM OF ACTION & ANTIMICROBIAL ACTIVITY: Sulfonamide-susceptible organisms, unlike mammals, cannot use exogenous folate but must synthesize it from PABA. This pathway is thus essential for production of purines and nucleic acid synthesis. Nucleic acids  As structural analogs of PABA, sulfonamides inhibit dihydropteroate synthase and thus folate production.

SPECTRUM OF ACTIVITY: Sulfonamides inhibit both gram-positive and gram-negative bacteria, Nocardia sp, Chlamydia trachomatis, and some protozoa. Some enteric bacteria, such as Escherichia coli, Klebsiella pneumoniae, Salmonella, Shigella, and Enterobacter sp are also inhibited. It is interesting to note however that rickettsiae are not inhibited by sulfonamides but are instead stimulated in their growth. The activity is poor against anaerobes. Pseudomonas aeruginosa is intrinsically resistant to sulfonamide antibiotics. Bacteriology: Antibiotics  Combination of a sulfonamide with an inhibitor of dihydrofolate reductase (trimethoprim or pyrimethamine) provides synergistic activity because of sequential inhibition of folate synthesis.

RESISTANCE: Mammalian cells and some bacterial cells lack the enzymes required for folate synthesis from PABA and depend on exogenous sources of folate; therefore, they are not susceptible to sulfonamides. Sulfonamide resistance may occur as a result of mutations that; (1) cause overproduction of PABA, (2) cause production of a folic acid-synthesizing enzyme that has low affinity for sulfonamides, or (3) impaired permeability to the sulfonamide.

CLINICAL USES: Sulfonamides are infrequently used as single agents. Many strains of formerly susceptible species, including meningococci, pneumococci, streptococci, staphylococci, and gonococci, are now resistant. Antimicrobial drug resistance  The fixed-drug combination of trimethoprim-sulfamethoxazole is the drug of choice for infections such as Pneumocystis jiroveci (formerly P. carinii) pneumonia, toxoplasmosis, nocardiosis, and occasionally other bacterial infections.

ORAL ABSORBABLE AGENTS: Sulfisoxazole and sulfamethoxazole are short- to medium-acting agents used almost exclusively to treat urinary tract infections. The usual adult dosage is 1 g of sulfisoxazole four times daily or 1 g of sulfamethoxazole two or three times daily. Sulfadiazine in combination with pyrimethamine is first-line therapy for treatment of acute toxoplasmosis. The combination of sulfadiazine with pyrimethamine, a potent inhibitor of dihydrofolate reductase, is synergistic because these drugs block sequential steps in the folate synthetic pathway blockade. The dosage of sulfadiazine is 1 g four times daily, with pyrimethamine given as a 75-mg loading dose followed by a 25-mg once-daily dose. Folinic acid, 10 mg orally each day, should also be administered to minimize bone marrow suppression. Sulfadoxine is the only long-acting sulfonamide currently available in many countries including sub Saharan Africa, and only as a combination formulation with pyrimethamine (Fansidar), a second-line agent in the treatment of malaria.

ORAL NONABSORBABLE AGENTS: Sulfasalazine (salicylazosulfapyridine) is widely used in ulcerative colitis, enteritis, and other inflammatory bowel disease.

TOPICAL AGENTS: Sodium sulfacetamide ophthalmic solution or ointment is effective in the treatment of bacterial conjunctivitis and as adjunctive therapy for trachoma. Another sulfonamide, mafenide acetate, is used topically but can be absorbed from burn sites. The drug and its primary metabolite inhibit carbonic anhydrase and can cause metabolic acidosis, a side effect that limits its usefulness. Silver sulfadiazine is a much less toxic topical sulfonamide and is preferred to mafenide for prevention of infection of burn wounds.

ADVERSE REACTIONS: All sulfonamides, including antimicrobial sulfas, diuretics, diazoxide, and the sulfonylurea hypoglycemic agents, have been considered to be partially cross-allergenic. The most common adverse effects are fever, skin rashes, exfoliative dermatitis, photosensitivity, urticaria, nausea, vomiting, diarrhea, and difficulties referable to the urinary tract. Other unwanted effects include stomatitis, conjunctivitis, arthritis, hematopoietic disturbances, hepatitis, and, rarely, polyarteritis nodosa and psychosis.

RELATED;

1.  Artemisinin and its derivatives

2.  Antibiotics

3.  Metronidazole

4.  Pharmacology and therapeutics

REFERENCES

ARTEMISININ & ITS DERIVATIVES

INTRODUCTION: Artemisinin is a sesquiterpene lactone endoperoxide, the active component of an herbal medicine that has been used as an antipyretic in China for over 2000 years. Artemisinin is insoluble and can only be used orally. However, analogs have been synthesized to increase solubility and improve antimalarial efficacy. The most important of these analogs are artesunate which is water-soluble and is useful for oral, intravenous, intramuscular, and rectal administration. The other one is artemether which is lipid-soluble and useful for oral, intramuscular, and rectal administration, and dihydroartemisinin which is water-soluble and useful for oral administration.

CHEMISTRY & PHARMACOKINETICS: Artemisinin and its analogs are rapidly absorbed, with peak plasma levels occurring in 1–2 hours and half-lives of 1–3 hours after oral administration. Artemisinin, artesunate, and artemether are rapidly metabolized to the active metabolite dihydroartemisinin. Drug levels appear to decrease after a number of days of therapy.

Artemether-lumefantrine (Coartem, Lumartem, Combiat, Riamet): Co-formulated; first-line therapy in many countries; approved in the USA

Artesunate-amodiaquine (ASAQ, Arsucam, Coarsucam): Co-formulated; first-line therapy in many African countries

Artesunate-mefloquine: Co-formulated; first-line therapy in parts of Southeast Asia and South America.

Dihydroartemisinin-piperaquine (Artekin, Duocotecxin): Co-formulated; first-line therapy in some countries in Southeast Asia

Artesunate-sulfadoxine-pyrimethamine: First-line therapy in some countries, but efficacy lower than other regimens in most areas.

CLINICAL USES: Artemisinin-based combination therapy is now the standard for treatment of uncomplicated falciparum malaria in nearly all areas endemic for falciparum malaria. These regimens were developed because the short plasma half-lives of the artemisinins led to unacceptably high recrudescence rates after short-course therapy, which were reversed by inclusion of longer-acting drugs. Combination therapy also helps to protect against the selection of artemisinin resistance. However, with completion of dosing after 3 days, the artemisinin components are rapidly eliminated, and so selection of resistance to partner drugs is of concern. The WHO recommends five artemisinin-based combinations for the treatment of uncomplicated falciparum malaria. One of these, artesunate-sulfadoxine-pyrimethamine is not recommended in many areas owing to unacceptable levels of resistance to sulfadoxine-pyrimethamine, but it is the first-line therapy in some countries in Asia, South America, and North Africa. The other four recommended regimens are now all available as combination formulations, although manufacturing standards may vary. Artesunate-mefloquine is highly effective in Southeast Asia, where resistance to many antimalarials is common; it is the first-line therapy in some countries in Southeast Asia and South America. This regimen is less practical for other areas, particularly Africa, because of its relatively high cost and poor tolerability. Either artesunate-amodiaquine or artemether-lumefantrine is now the standard treatment for uncomplicated falciparum malaria in most countries in Africa and some additional endemic countries on other continents. Dihydroartemisinin-piperaquine is a newer regimen that has shown excellent efficacy; it is the first-line therapy for falciparum malaria in Vietnam. T he relative efficacy and safety of artemisinin-based combination therapies are now under active investigation. In general, the leading regimens are highly efficacious, safe, and well tolerated, and they are the new standard of care for the treatment of uncomplicated falciparum malaria. Artemisinins are also proving to have outstanding efficacy in the treatment of complicated falciparum malaria. Large randomized trials and meta-analyses have shown that intramuscular artemether has an efficacy equivalent to that of quinine and that intravenous artesunate is superior to intravenous quinine in terms of parasite clearance time and—most important—patient survival. Intravenous artesunate also has a superior side-effect profile compared with that of intravenous quinine or quinidine. Thus, intravenous artesunate will likely replace quinine as the standard of care for the treatment of severe falciparum malaria, although it is not yet widely available in most areas. Artesunate and artemether have also been effective in the treatment of severe malaria when administered rectally, offering a valuable treatment modality when parenteral therapy is not available.

ADVERSE EFFECTS & CAUTIONS: Artemisinins are generally very well tolerated. The most commonly reported adverse effects are nausea, vomiting, diarrhea, and dizziness, and these may often be due to underlying malaria rather than the medications. Rare serious toxicities include neutropenia, anemia, hemolysis, elevated liver enzymes, and allergic reactions. Irreversible neurotoxicity has been seen in animals, but only after doses much higher than those used to treat malaria. Artemisinins have been embryotoxic in animal studies, but rates of congenital abnormalities, stillbirths, and abortions were not elevated, compared with those of controls, in women who received artemisinins during pregnancy. Based on this information and the significant risk of malaria during pregnancy, the WHO recommends artemisininbased combination therapies for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy, intravenous artesunate or quinine for the treatment of severe malaria during the first trimester, and intravenous artesunate for treatment of severe malaria during the second and third trimesters.

RELATED;

1.  PENICILLINS  

2.  AZITHROMYCIN

3.  PHARMACOLOGY AND THERAPEUTICS

REFERENCES

AZITHROMYCIN

 

Introduction: Azithromycin, a 15-atom lactone macrolide ring compound, is derived from erythromycin by addition of a methylated nitrogen into the lactone ring. Its spectrum of activity, mechanism of action, and clinical uses are similar to those of clarithromycin. Azithromycin is active against M. avium complex and T. gondii. Mycobacteria:  Azithromycin is slightly less active than erythromycin and clarithromycin against staphylococci and streptococci and slightly more active against H. influenzae. Azithromycin is highly active against Chlamydia sp. H.influenzae

Pharmacokinetic aspects of the drug: Azithromycin differs from erythromycin and clarithromycin mainly in pharmacokinetic properties. A 500-mg dose of azithromycin produces relatively low serum concentrations of approximately 0.4 mcg/mL. However, azithromycin penetrates into most tissues (except cerebrospinal fluid) and phagocytic cells extremely well, with tissue concentrations exceeding serum concentrations by 10- to 100-fold. The drug is slowly released from tissues (tissue half-life of 2–4 days) to produce an elimination half-life approaching 3 days. These unique properties permit once-daily dosing and shortening of the duration of treatment in many cases. For example, a single 1-g dose of azithromycin is as effective as a 7-day course of doxycycline for chlamydial cervicitis and urethritis.

Pharmacological Applications: Community-acquired pneumonia can be treated with azithromycin given as a 500-mg loading dose, followed by a 250-mg single daily dose for the next 4 days. A zithromycin is rapidly absorbed and well tolerated orally. It should be administered 1 hour before or 2 hours after meals. Aluminum and magnesium antacids do not alter bioavailability but delay absorption and reduce peak serum concentrations. Azithromycin does not inactivate cytochrome P450 enzymes and, therefore, is free of the drug interactions that occur with erythromycin and clarithromycin.  

RELATED;

1.  The cytochrome P450 enzyme system

2.  Pharmacology test questions

3.  Pharmacology and therapeutics

[REFERENCE]

METFORMIN

 

ACTIONS AND USES: Metformin is a preferred oral antidiabetic drug for managing type 2 DM because of its effectiveness and safety. It is used alone or in combination with other antidiabetic medications or insulin. It is approved for use in children age 10 or above. It is available as regular-release tablets, solution, and sustained-release forms. Metformin reduces fasting and postprandial glucose levels by decreasing the hepatic production of glucose by the process of gluconeogenesis and reducing insulin resistance. It does not promote insulin release from the pancreas. A major advantage of the drug is that it does not cause hypoglycemia. The drug's actions do not depend on stimulating insulin release, so it is able to lower glucose levels in patients who no longer secrete insulin. In addition to lowering blood glucose levels, it lowers triglyceride and total and low-density lipoprotein (LDL) cholesterol levels, and it promotes weight loss. Metformin reduces insulin resistance, which in turn lowers insulin and androgen levels, thus restoring normal menstrual cycles and ovulation.

ADMINISTRATION ALERTS: Sustained-release tablets must be swallowed whole and not crushed or chewed. Fasting blood glucose levels should be obtained every 3 months, and the dose adjusted accordingly. Discontinue the medication immediately if signs of acidosis are present. Pregnancy category B.

PHARMACOKINETICS: Onset Peak Duration Less than 1 h 1–3 h (regular release); 4–8 h (extended release) 12 h (regular release); 24 h (extended release)

ADVERSE EFFECTS: The most common adverse effects are GI related and include nausea, vomiting, abdominal discomfort, metallic taste, diarrhea, and anorexia. It may also cause headache, dizziness, agitation, and fatigue. Unlike the sulfonylureas, metformin rarely causes hypoglycemia or weight gain.

Warning: Lactic acidosis is a rare, though potentially fatal, adverse effect. The risk for lactic acidosis is increased in patients with renal insufficiency or any condition that puts them at risk for increased lactic acid production, such as liver disease, severe infection, excessive alcohol intake, shock, or hypoxemia.

RELATED;

1. DIABETES MELLITUS

2. INSULIN

3.  PATHOPHYSIOLOGY OF DIABETES

4.  PHARMACOLOGY AND THERAPEUTICS